Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Patient-derived organoids guide personalized therapy for KRAS-mutant pancreatic cancer: synergistic MEK/mTOR inhibition and predictive chemotherapy responses.

Frontiers in immunology - 1 Jan 2026

Wang Xiaorui, Liu Lijuan, Li Feng, Da Yanyan, Hu Fang, Qi Xin, Pan Yiwen, Jiang Meng, Hou Peng, Yang Jin

Abstract excerpt

Introduction: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy driven by KRAS mutations in ~90% of cases, with high heterogeneity and limited efficacy of single targeted agents. Patient-derived organoids (PDOs) and xenografts (PDXs) offer promising platforms for personalized therapy by replicating tumor characteristics. Methods: We established a PDAC biobank with 69% PDO and 31% PDX success...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Deoxycytidine
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Flavonoids

Share to Morpholines

Share to Organoids

Share to Piperidines

Share to Pyridones

Share to Pyrimidinones

Source

Open in PubMed Open full text

Identifiers

PMID: 42220503
DOI: 10.3389/fimmu.2026.1760379
PMCID: PMC13218876

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Patient-derived organoids guide personalized therapy for KRAS-mutant pancreatic cancer: synergistic MEK/mTOR inhibition and predictive chemotherapy responses.PMID 42220503Read ↗

Combining molecular characteristics and therapeutic analysis of PDOs predict clinical responses and guide PDAC personalized treatmentSemantic proximity Read ↗

The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant therapy.Semantic proximity Read ↗

Pancreatic adenocarcinoma human organoids share structural and genetic features with primary tumorsSemantic proximity Read ↗

Organoids for Functional Precision Medicine in Advanced Pancreatic Cancer.Semantic proximity Read ↗

Establishing 3D organoid models from patient-derived conditionally reprogrammed cells to bridge preclinical and clinical insights in pancreatic cancerSemantic proximity Read ↗

Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma TumorsSemantic proximity Read ↗

Patient-derived Tumor Xenograft and Organoid Models Established from Resected Pancreatic, Duodenal and Biliary CancersSemantic proximity Read ↗

Establishment and Thorough Characterization of Xenograft (PDX) Models Derived from Patients with Pancreatic Cancer for Molecular Analyses and Chemosensitivity TestingSemantic proximity Read ↗

Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic CancerSemantic proximity Read ↗

Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers.Semantic proximity Read ↗

Establishing 3D Organoid Models from Patient-Derived Conditionally Reprogrammed Cells to Bridge Preclinical and Clinical Insights in Pancreatic CancerSemantic proximity Read ↗

Tumor organoids improve mutation detection of pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.